Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
15 USD | +0.23% | -1.39% | +2.61% |
31/05 | Needham Trims Price Target on Celcuity to $23 From $24, Maintains Buy Rating | MT |
30/05 | Sector Update: Health Care Stocks Mixed Pre-Bell Thursday | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+2.61% | 525M | |
+15.64% | 121B | |
+13.50% | 107B | |
-5.38% | 24.82B | |
+1.69% | 22.48B | |
-10.09% | 18.32B | |
-40.52% | 16.33B | |
-14.52% | 15.31B | |
+3.11% | 14.08B | |
+25.01% | 11.74B |
- Stock Market
- Equities
- CELC Stock
- News Celcuity Inc.
- Celcuity Says Phase 1b Gedatolisib Trial With Letrozole, Palbociclib Met Safety and Efficacy Endpoints in Breast Cancer Patients